Search

Puma Biotechnology Inc

Lezárt

SzektorEgészségügy

8.82 1.73

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

8.61

Maximum

8.93

Fő mutatók

By Trading Economics

Bevétel

12M

8.2M

Értékesítés

12M

57M

P/E

Szektor átlag

17.38

57.002

Egy részvényre jutó nyereség

0.16

Profit margin

14.493

Munkavállalók

179

EBITDA

14M

14M

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

-32.58% downside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

45M

449M

Előző nyitás

7.09

Előző zárás

8.82

Hangulat hírek alapján

By Acuity

26%

74%

77 / 340 Rangsor szerint Healthcare

Puma Biotechnology Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 13. 19:26 UTC

Puma Biotechnology Inc shares are lower today, following an early peak. Broader market data showed rising jobless claims and flat producer price index growth.

2026. aug. 12. 19:46 UTC

Puma Biotechnology Inc shares are higher today, supported by positive market sentiment following a favorable inflation report. Earlier, shares pulled back from session highs.

2026. aug. 11. 22:01 UTC

Puma Biotechnology Inc shares declined in after-market trading, continuing a downward trend since Tuesday's close, amid no specific news to explain the movement.

2026. aug. 10. 20:06 UTC

Puma Biotechnology Inc. shares are lower today, reflecting broader market trends amid an unexpected decline in U.S. jobs and inflation reassessments.

2026. aug. 7. 20:02 UTC

News

Puma Biotechnology shares rise following strong earnings and TD Cowen's price target increase to $6.00. Trading volume indicates heightened investor interest.

2026. aug. 6. 19:26 UTC

Puma Biotechnology Inc shares are higher Thursday, maintaining upward momentum after three consecutive gains, despite a pullback earlier in the session.

2026. aug. 5. 21:51 UTC

News

Puma Biotechnology shares are trading lower in after-market hours following the grant of stock awards to new employees, which may dilute existing shareholder value.

2026. aug. 4. 19:56 UTC

Puma Biotechnology Inc is trading higher today, benefiting from a decline in crude oil prices that eased inflation concerns. Shares earlier pulled back from a session high.

2026. aug. 3. 19:51 UTC

Puma Biotechnology Inc shares are lower today, reflecting a decline since Friday. The stock saw significant volatility, initially rising before dropping sharply.

2026. júl. 31. 19:16 UTC

Puma Biotechnology Inc shares are lower today, continuing a decline since Thursday's close. The stock is trading near the lower end of its one-month range.

2026. júl. 30. 18:31 UTC

Puma Biotechnology Inc shares are higher as the overall market recovers from recent declines. The stock remains below its 20-day moving average.

2026. júl. 29. 18:23 UTC

Puma Biotechnology Inc shares are lower amid broader market weakness as investors await the Federal Reserve's interest rate decision this afternoon.

2026. júl. 28. 18:06 UTC

Puma Biotechnology shares are lower amid broader market trends, influenced by declines in Asian markets, particularly in technology sectors.

2026. júl. 27. 19:46 UTC

Puma Biotechnology Inc shares are higher, reflecting broader market gains amid a significant decline in crude oil prices following geopolitical developments.

2026. júl. 24. 19:26 UTC

Puma Biotechnology Inc. shares are roughly flat as no specific news emerged during Friday's trading session, fluctuating within a routine range.

2026. júl. 23. 20:06 UTC

Puma Biotechnology Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday's close amid no specific news identified.

2026. júl. 22. 22:51 UTC

Puma Biotechnology Inc shares are trading higher in after-market hours, building on earlier gains. The stock remains above its 20-day moving average.

2026. júl. 21. 18:02 UTC

Puma Biotechnology Inc shares are higher during Tuesday's session, continuing a positive trend since Monday. The stock remains above its 20-day moving average.

2026. júl. 20. 20:06 UTC

Puma Biotechnology Inc shares are lower today, having reached a mid-day low of -4.46%. No specific news has been identified to explain the decline.

Társak összehasonlítása

Árváltozás

Puma Biotechnology Inc Előrejelzés

Célár

By TipRanks

-32.58% elmozdulás lefelé

12 hónapos előrejelzés

Átlag 6 USD  -32.58%

Magas 6 USD

Alacsony 6 USD

1 Wall Street elemző 12 hónapos célárain alapulva a(z)Puma Biotechnology Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

1 ratings

0

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

77 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat